Medical Xpress·4 min read·hard
Tumor-on-a-chip method reveals timing as a factor in glioblastoma immunotherapy
S
Sungkyunkwan University
✦AI Summary
Researchers have developed a 'tumor-on-a-chip' microfluidic platform to study how the timing of immune cell interactions affects glioblastoma treatment. The study found that the sequence in which immune cells are introduced to cancer cells significantly alters the effectiveness of immunotherapy.
edited by Sadie Harley , reviewed by Robert Egan
sciencehealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in